X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cabenuva is a combination of cabotegravir which inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration which is essential for HIV replication and rilpivirine which inhibits HIV-1 reverse transcriptase.
Lead Product(s): Cabotegravir,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Product Name: Cabenuva
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Apretude (cabotegravir) is an integrase strand transfer inhibitor, long acting injection, which is being evaluated for the treatment of HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Apretude
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for the treatment of HIV-associated tuberculosis.
Lead Product(s): Dolutegravir Sodium,Rifapentine,Moxifloxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Tivicay
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: ACTG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Dolutegravir tablets is a HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Lead Product(s): Dolutegravir Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Tivicay-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AIDS Healthcare Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Details:
Apretude (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI), which is indicated for the treatment of sexually acquired HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Apretude
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
CAB LA (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI). INSTIs, like cabotegravir extended-release injectable suspension, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Product Name: CAB LA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
Through the agreement, the selected generic manufacturers, Aurobindo, Cipla and Viatris, will be able to develop, manufacture, and supply generic versions of cabotegravir LA for PrEP, in 90 countries, subject to required regulatory approvals being obtained.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Cabotegravir-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Medicines Patent Pool
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 30, 2023
Details:
Cabenuva is a combination of cabotegravir which inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration which is essential for HIV replication and rilpivirine which inhibits HIV-1 reverse transcriptase.
Lead Product(s): Cabotegravir,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Product Name: Cabenuva
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
Biktarvy is a combination of bictegravir which targets HIV-1 integrase thus inhibiting HIV virus replication, emtricitabine and tenofovir alafenamide which inhibits the activity of the HIV-1 reverse transcriptase resulting in DNA chain termination.
Lead Product(s): Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area: Infections and Infectious Diseases Product Name: Biktarvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
GSK3810109A (VH3810109), a novel, investigational, broadly neutralising antibody (bNAb) that is being studied at two dosing levels – a high dose and ten-fold lower dose (40 mg/kg and ~4 mg/kg (280 mg), respectively), in adults living with HIV.
Lead Product(s): GSK3810109A
Therapeutic Area: Infections and Infectious Diseases Product Name: VH3810109
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
